Prevalence of Nonalcoholic Fatty Liver Disease and its Related Metabolic Risk Factors in Isfahan, Iran

Document Type : Original Article


1 Department of Radiology, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Gastroenterology, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Department of Nutrition and Dietetics, School of Healthcare Sciences, National University of Malaysia, Selangor, Malaysia

4 Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran


Background: This study aimed to determine the prevalence of nonalcoholic fatty liver disease (NAFLD) and its related risk factors among the general population of Isfahan city located in the central part of Iran. Materials and Methods: In this cross-sectional study, the prevalence of NAFLD among 483 general adult populations was determined using ultrasonography. Anthropometric and biochemical variables were compared in groups with and without NAFLD and their predictive value for occurrence of NAFLD was investigated also. Results: Prevalence of NAFLD was 39.3%. Frequency of focal fatty infiltration (FFI), Grade I, Grade II, and Grade III of NAFLD was 9.5%, 21.1%, 7.2%, 1.4%, respectively. Prevalence of different types of NAFLD and FFI, was not different between female and male participants (P = 0.238). Ordinal regression was determined that all of the studied variables have significant predictive value for NAFLD (P < 0.001, γ = 0.615). Spearman correlation indicated that there was a significant relationship between NAFLD and BMI (r = 0.37, P< 0.001), age (r = 0.15, P = 0.001), FBS (r = 0.20, P< 0.001), cholesterol (r = 0.19, P< 0.001), triglyceride (r = 0.20, P< 0.001), LDL (r = 0.16, P< 0.001), AST (r = 0.17, P< 0.001), and ALT (r = 0.31, P< 0.001). Conclusions: Considering the high prevalence of NAFLD specially its lower grades among Isfahani adult general population and their association with studied variables, it seems that interventional studies which target-related mentioned risk factors could reduce the overall occurrence of NAFLD.


Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344-53.  Back to cited text no. 1
Khedmat H, Taheri S. Non-alcoholic steatohepatitis: An update in pathophysiology, diagnosis and therapy. Hepat Mon 2011;11:74-85.  Back to cited text no. 2
Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: Pathology and pathogenesis. Annu Rev Pathol 2010;5:145-71.  Back to cited text no. 3
Alavian SM, Motlagh ME, Ardalan G, Motaghian M, Davarpanah AH, Kelishadi R. Hypertriglyceridemic waist phenotype and associated lifestyle factors in a national population of youths: CASPIAN Study. J Trop Pediatr 2008;54:169-77.  Back to cited text no. 4
Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 2006;43 2 Suppl 1:S99-112.  Back to cited text no. 5
Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: A global perspective. Semin Liver Dis 2008;28:339-50.  Back to cited text no. 6
Alavian SM, Mohammad-Alizadeh AH, Esna-Ashari F, Ardalan G, Hajarizadeh B. Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures. Liver Int 2009;29:159-63.  Back to cited text no. 7
Sohrabpour A, Rezvan H, Amini-Kafiabad S, Dayhim M, Merat S, Pourshams A. Prevalence of nonalcoholic steatohepatitis in Iran: A population based study. Middle East J Dig Dis 2010;2:14-9.  Back to cited text no. 8
Crabb DW, Galli A, Fischer M, You M. Molecular mechanisms of alcoholic fatty liver: Role of peroxisome proliferator-activated receptor alpha. Alcohol 2004;34:35-8.  Back to cited text no. 9
Li H, Wang YJ, Tan K, Zeng L, Liu L, Liu FJ, et al. Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China. Hepatobiliary Pancreat Dis Int 2009;8:377-82.  Back to cited text no. 10
Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: The plot thickens. Diabet Med 2007;24:1-6.  Back to cited text no. 11
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592-609.  Back to cited text no. 12
Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: A new and important cardiovascular risk factor? Eur Heart J 2012;33:1190-200.  Back to cited text no. 13
Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.  Back to cited text no. 14
Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008;49:608-12.  Back to cited text no. 15
Pacana T, Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2012;15:641-8.  Back to cited text no. 16
Kemmer N, Neff GW, Franco E, Osman-Mohammed H, Leone J, Parkinson E, et al. Nonalcoholic fatty liver disease epidemic and its implications for liver transplantation. Transplantation 2013;96:860-2.  Back to cited text no. 17
Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986;292:13-5.  Back to cited text no. 18
Sanyal AJ; American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25.  Back to cited text no. 19
Kennedy G. Non-alcoholic fatty liver disease: Can ultrasound assist in early diagnosis of prediabetes and delay progression to type 2 diabetes mellitus. Sound Effects; 2009.  Back to cited text no. 20
Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology 2011;54:1082-90.  Back to cited text no. 21
Bellentani S, Bedogni G, Miglioli L, Tiribelli C. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 2004;16:1087-93.  Back to cited text no. 22
Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007;13:6419-24.  Back to cited text no. 23
Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004;40:1387-95.  Back to cited text no. 24
Omagari K, Kadokawa Y, Masuda J, Egawa I, Sawa T, Hazama H, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: Incidence and clinical characteristics. J Gastroenterol Hepatol 2002;17:1098-105.  Back to cited text no. 25
Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006;21(1 Pt 1):138-43.  Back to cited text no. 26
Rogha M, Najafi N, Azari A, Kaji M, Pourmoghaddas Z, Rajabi F, et al. Non-alcoholic steatohepatitis in a sample of Iranian adult population: Age is a risk factor. Int J Prev Med 2011;2:24-7.  Back to cited text no. 27
Lankarani KB, Ghaffarpasand F, Mahmoodi M, Lotfi M, Zamiri N, Heydari ST, et al. Non alcoholic fatty liver disease in Southern Iran: A population based study. Hepat Mon 2013;13:e9248.  Back to cited text no. 28
Amirkalali B, Poustchi H, Keyvani H, Khansari MR, Ajdarkosh H, Maadi M, et al. Prevalence of non-alcoholic fatty liver disease and its predictors in North of Iran. Iran J Public Health 2014;43:1275-83.  Back to cited text no. 29
Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract 2003;61:29-37.  Back to cited text no. 30
Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009;50:204-10.  Back to cited text no. 31
Feldman M, Friedman LS, Brandt LJ. Nonalcoholic fatty liver disease. Gastrointestinal and Liver Disease. 8th ed. Canada: Saunders; 2006. p. 1793-805.  Back to cited text no. 32
García-Monzón C, Martín-Pérez E, Iacono OL, Fernández-Bermejo M, Majano PL, Apolinario A, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000;33:716-24.  Back to cited text no. 33
Kabir M, Catalano KJ, Ananthnarayan S, Kim SP, Van Citters GW, Dea MK, et al. Molecular evidence supporting the portal theory: A causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 2005;288:E454-61.  Back to cited text no. 34
Tung T, Chiu W, Lin T, Shih H, Hsu C. An exploration of prevalence and associated factors of nonalcoholic fatty liver disease in the Taiwanese police service. Iran J Public Health 2011;40:54-62.  Back to cited text no. 35
Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: A multicenter large retrospective study. J Gastroenterol 2012;47:586-95.  Back to cited text no. 36
Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006;26:856-63.  Back to cited text no. 37
Lin YC, Chou SC, Huang PT, Chiou HY. Risk factors and predictors of non-alcoholic fatty liver disease in Taiwan. Ann Hepatol 2011;10:125-32.  Back to cited text no. 38
Kwon YM, Oh SW, Hwang SS, Lee C, Kwon H, Chung GE. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am J Gastroenterol 2012;107:1852-8.  Back to cited text no. 39
Ghamar-Chehreh ME, Khedmat H, Amini M, Taheri S. Predictive factors for ultrasonographic grading of nonalcoholic fatty liver disease. Hepat Mon 2012;12:e6860.  Back to cited text no. 40
Razavizade M, Jamali R, Arj A, Talari H. Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 2012;11:513-20.  Back to cited text no. 41
Abangah G, Yousefi A, Asadollahi R, Veisani Y, Rahimifar P, Alizadeh S. Correlation of body mass index and serum parameters with ultrasonographic grade of fatty change in non-alcoholic fatty liver disease. Iran Red Crescent Med J 2014;16:e12669.  Back to cited text no. 42
Hashemi Kani A, Alavian SM, Esmaillzadeh A, Adibi P, Azadbakht L. Dietary quality indices and biochemical parameters among patients with non alcoholic fatty liver disease (NAFLD). Hepat Mon 2013;13:e10943.  Back to cited text no. 43
Lee S, Jin Kim Y, Yong Jeon T, Hoi Kim H, Woo Oh S, Park Y, et al. Obesity is the only independent factor associated with ultrasound-diagnosed non-alcoholic fatty liver disease: A cross-sectional case-control study. Scand J Gastroenterol 2006;41:566-72.  Back to cited text no. 44
Sogabe M, Okahisa T, Tsujigami K, Fukuno H, Hibino S, Yamanoi A. Visceral fat predominance is associated with non-alcoholic fatty liver disease in Japanese women with metabolic syndrome. Hepatol Res 2014;44:515-22.  Back to cited text no. 45
Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266-71.  Back to cited text no. 46
Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Bahram Kalhori A, et al. Persistent alanine aminotransferase elevation among the general Iranian population: Prevalence and causes. World J Gastroenterol 2008;14:2867-71.  Back to cited text no. 47
Ye J, Chen Z, Wang T, Tong J, Li X, Jiang J, et al. Role of tissue disorder markers in the evaluation of disease progress and outcome prediction: A prospective cohort study in non-cardiac critically ill patients. J Clin Lab Anal 2010;24:376-84.  Back to cited text no. 48
Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res 2012;2012:145754.  Back to cited text no. 49
Ghamar-Chehreh ME, Amini M, Khedmat H, Moayed Alavian S, Daraei F, Mohtashami R, et al. Elevated alanine aminotransferase activity is not associated with dyslipidemias, but related to insulin resistance and higher disease grades in non-diabetic non-alcoholic fatty liver disease. Asian Pac J Trop Biomed 2012;2:702-6.  Back to cited text no. 50